CARDS: Sub-study in Diabetics with Renal Impairment

18 Aug, 10

CARDS: Sub-study in Diabetics with Renal Impairment

Background

Atorvastatin Reduces the Risk of Major Cardiovascular Events in Patients with Diabetes and Impaired Renal Function: Subanalysis of Collaborative Atorvastatin Diabetes Study (CARDS)

Aim

To evaluate the efficacy of atorvastatin in type 2 diabetic patients with renal impairment and no prior cardiovascular disease

Patients

Type 2 diabetics with estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m^₂ at baseline (N=967)

Results

Atorvastatin 10 mg significantly reduced the risk of MCVE by 48%, including a 42% reduction in acute coronary heart disease event, a 62% reduction in stroke and a 59% reduction in coronary revascularisation (Figure); effects similar to those observed in patients with normal renal function

Figure. Effect of atorvastatin on cardiovascular outcomes

Conclusion

Atorvastatin 10 mg daily is equally efficacious in reducing coronary heart disease and stroke in diabetic patients with impaired renal function as in those with normal or near normal renal function.

Presented at 67th Scientific Sessions of ADA, June 22-26, 2007. Presentation Title "Atorvastatin Reduces the Risk of Major Cardiovascular Events in Patients With Diabetes and Impaired Renal Function in the Collaborative Atorvastatin Diabetes Study (CARDS)". Abstract number 0524-P

CARDS: Sub-study in Diabetics with Renal Impairment

CARDS: Sub-study in Diabetics with Renal Impairment

Background

Aim

Patients

Study Groups

Median Follow-up Period

End-point

Results

Conclusion